Clearside Biomedical, Inc. Announces Third Patent Allowance in the U.S. Related to Proprietary Microneedle Drug Delivery Methods and Devices
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/453,407 as U.S. Patent No. 8,636,713 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the third patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices.
“Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle.”
U.S. Patent No. 8,636,713 provides exclusivity through May 2, 2027, and covers in part, a method of administering an anti-inflammatory drug to an eye of a patient by inserting a hollow microneedle into the patient’s eye, and infusing the drug into the suprachoroidal space of the patient’s eye. The patent, exclusively licensed to Clearside, is the third generated from Clearside’s alliance with the Georgia Tech Research Corporation and Emory University.
In April 2011 and June 2012, the USPTO issued method and device patents covering the Company's drug delivery methods and devices for carrying out the methods.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics to the choroid and retina using a proprietary microinjection dosage form. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with choroidal and retinal disease. Visit www.clearsidebio.com for more information.